Phase 4 Ankylosing Spondylitis Trial, Recruiting NCT06707194 Sponsor: Nanfang Hospital, Southern Medical University Condition: Ankylosing Spondylitis
Back to Ankylosing Spondylitis

Phase 4 Ankylosing Spondylitis Trial, Recruiting

NCT06707194
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have signed a consent form agreeing to participate.
  • You are between 18 and 59 years old.
  • You have been diagnosed with spinal arthritis (also called spondyloarthritis) using recognised medical guidelines — either affecting the spine/pelvis or the joints in other parts of the body.
  • Your spinal arthritis is currently in an active phase, meaning a specific blood and symptom score (ASDAS-CRP) shows your condition is active enough to qualify (confirm with trial site).

Who may not be able to join:

  • You have certain other health conditions, including throat/nasal infections, active tuberculosis, inflammatory bowel disease, other rheumatic or immune system diseases, cancer, or other bone and joint diseases.
  • You are known to be allergic to any ingredients in the study drug being tested.
  • Your liver or kidney function test results are significantly abnormal — specifically, certain liver enzyme or kidney levels that are more than twice the normal range.
  • You are pregnant, trying to become pregnant, or currently breastfeeding.
  • You have moderate to severe heart failure (a serious level of heart weakness, confirmed by a doctor's grading system).
  • You have an active stomach or intestinal ulcer, or are experiencing gastrointestinal bleeding.
  • You currently show signs of a streptococcal infection (such as severe sore throat, tonsillitis, scarlet fever, or a skin infection caused by streptococcal bacteria), with abnormal related blood test results.
  • The trial researchers decide for any other reason that the study drug or the trial is not suitable for you.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 0086-20-18665000156

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Nanfang Hospital, Southern Medical University
Registry
ClinicalTrials.gov
Start date
14 June 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Patient ASAS40 remission rate after 12 weeks of patient medication

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov